Home » THERAVANCE, GSK BEGIN ASTHMA CLINICAL PROGRAM
THERAVANCE, GSK BEGIN ASTHMA CLINICAL PROGRAM
Theravance and GlaxoSmithKline (GSK) have enrolled the first patient in a Phase IIb clinical program with the investigational long-acting beta agonist (LABA) compound, 159797 ('797), in patients with mild-to-moderate asthma.
The companies will develop a once-a-day inhaled combination medicine comprised of a LABA and a corticosteroid. This step is part of the next phase in the collaboration, which will determine the LABA to take into the combination clinical trials program in patients.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May